Chitosan Hemostatic Gel for Hidden Jaw Hemangioma Bleeding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing hemostatic materials struggle to quickly reach and effectively stop hemorrhages in the complex and hidden hemorrhage points of jaw central hemangioma, often leading to severe bleeding during procedures like tooth extraction, and current embolization methods risk damaging vital blood vessels.
Innovation Solution
A chitosan-based hemostatic agent with good fluidity and plasticity, prepared by reacting chitosan powder with organic weak acid and carboxymethyl chitosan, which forms a gel-like coagulation block to press against the hemorrhage point, providing rapid hemostasis and bacterial inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If existing hemostatic materials are used, then hemostasis can be achieved, but they cannot quickly reach the hidden hemorrhage points in the complex spatial structure of the alveolar fossa
Solution Approach 1:
The patent changes the physical state parameter of the hemostatic material from solid particles to a fluid state with specific viscosity characteristics. The fluid hemostatic material can flow into the complex alveolar fossa structure and reach hidden hemorrhage points quickly, while the viscosity parameter ensures it remains retainable at the target site.
2Reliability
If compression hemostasis and surgical ligation are used, then hemorrhage can be stopped, but surgical treatment requires removal of most jaw and teeth, causing local depression deformity and dysfunction
Solution Approach 1:
The patent extracts the hemostatic function from complex surgical procedures and concentrates it into a simple fluid material application. The hemostatic material directly stops bleeding at the hemorrhage point without requiring removal of jaw or teeth, eliminating the harmful side effects of aggressive surgical intervention.
3Reliability
If embolization therapy is used, then emergency hemostasis can be achieved, but the cannula cannot enter the blood supply artery, causing wrong embolization of important blood vessels
Solution Approach 1:
The patent uses fluid hemostatic material as an intermediary substance that can be easily introduced into the alveolar fossa and automatically reach the hemorrhage point through capillary action and pressure gradient, avoiding the need for complex cannula insertion into blood supply arteries.
4Reliability
If hemostatic material is applied to jaw central blood vessel hemorrhage, then hemostasis can be achieved, but the material must form certain pressure at the hemorrhage point to effectively stop spraying hemorrhage
Solution Approach 1:
The patent optimizes the viscosity parameter of the hemostatic material to achieve the right balance: low enough to flow into the alveolar fossa and reach the hemorrhage point, but high enough to form adequate pressure at the target site to stop spraying hemorrhage effectively.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hemostatic agent quickly reaches and stops hemorrhages without tissue damage, inhibits bacterial growth, and prevents complications, maintaining facial structure and function, thus enhancing patient quality of life.
Implementation Method 1
Add chitosan powder and organic weak acid into organic alcohol, react at 40 to 50° C. for 3 to 5 h
Implementation Method 2
forms a gel-like coagulation block to press against the hemorrhage point
Implementation Method 3
forms a gel-like coagulation block
Implementation Method 4
The hemostatic agent quickly reaches and stops hemorrhages without tissue damage
Data Source
AI summary
The invention relates to the field of biomedical engineering, and discloses a hemostatic agent for jaw central hemangioma hemorrhage and a preparation method and application thereof. The invention is as follows: chitosan powder and organic weak acid are added into organic alcohol to react, so as to prepare chitosan weak acid salt, and then the chitosan weak acid salt is mixed with carboxymethyl chitosan in proportion to obtain the hemostatic agent of the invention. The hemostatic agent of the invention has good fluidity and plasticity. When applied to the hemostasis of jaw central hemangioma hemorrhage, the hemostatic agent of the invention can quickly reach the point of jaw central hemangioma hemorrhage without any stimulation and damage to the tissue. In addition, the hemostatic agent of the invention can inhibit the growth of bacteria, eliminate cross infection, and is easy to clean and remove. Therefore, the hemostatic agent of the invention can safely and effectively treat the massive hemorrhage of jaw central hemangioma, which is worthy of clinical promotion. At the same time, the hemostatic agent of the invention can also be used for hemostasis of hemorrhage points in tissue cavities with special structures.